The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics

Leukemia Research

Volumn 36, Issue 1, 2012, Pages

  Mori, Masanori ^a   Sprague, Julian ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; SORAFENIB;

ACUTE ERYTHROID LEUKEMIA; ADULT; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CYTOGENETICS; CYTOPENIA; DRUG EFFICACY; ERYTHROID CELL; FEMALE; FMS LIKE TYROSINE KINASE 3 GENE; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERNAL TANDEM DUPLICATION; KARYOTYPE 46,XX; LETTER; LEUKEMIA; LEUKEMIA REMISSION; LONG TERM CARE; MYELOBLAST; ONCOGENE; PRIORITY JOURNAL; TREATMENT DURATION; WHOLE BODY RADIATION;

ABNORMAL KARYOTYPE; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; ERYTHROID CELLS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MIDDLE AGED; PYRIDINES; REMISSION INDUCTION; TANDEM REPEAT SEQUENCES; TIME FACTORS; TREATMENT OUTCOME;

EID: 83555172360     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.023     Document Type: Letter

References (10)

1. Stirewalt D.K., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
2. Arber D.A., Brunning R.D., Le Beau M.M., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 116. WHO Press. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Thlede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
5. Zhang W., Konopleva M., McQueen T., et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
6. Metzelder S., Wang Y., Wollner E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
7. Auclair D., Miller D., Yatsula V., et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007, 21:439-445.
8. Knapper S. FLT3 inhibition in acute myeloid leukaemia. Br J Haematol 2007, 138:687-699.
9. Levis M., Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003, 17:178-1752.
10. + acute myeloid leukemia. Leuk Res 2009, 33:38-350.